Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 124

1.

Aripiprazole as an augmentation agent in treatment-resistant body dysmorphic disorder.

Uzun O, Ozdemir B.

Clin Drug Investig. 2010;30(10):707-10. doi: 10.2165/11536730-000000000-00000.

PMID:
20701402
[PubMed - indexed for MEDLINE]
2.

Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder.

Papakostas GI, Petersen TJ, Kinrys G, Burns AM, Worthington JJ, Alpert JE, Fava M, Nierenberg AA.

J Clin Psychiatry. 2005 Oct;66(10):1326-30.

PMID:
16259548
[PubMed - indexed for MEDLINE]
3.

Aripiprazole augmentation in 13 patients with refractory obsessive-compulsive disorder: a case series.

Higuma H, Kanehisa M, Maruyama Y, Ishitobi Y, Tanaka Y, Tsuru J, Hanada H, Kodama K, Isogawa K, Akiyoshi J.

World J Biol Psychiatry. 2012 Jan;13(1):14-21. doi: 10.3109/15622975.2010.551667.

PMID:
22256827
[PubMed - indexed for MEDLINE]
4.

A case series of aripiprazole augmentation of selective serotonin reuptake inhibitors in treatment-refractory obsessive compulsive disorder.

Matsunaga H, Hayashida K, Maebayashi K, Mito H, Kiriike N.

Int J Psychiatry Clin Pract. 2011 Nov;15(4):263-9. doi: 10.3109/13651501.2011.605958. Epub 2011 Aug 31.

PMID:
22121999
[PubMed - indexed for MEDLINE]
5.

Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study.

Pessina E, Albert U, Bogetto F, Maina G.

Int Clin Psychopharmacol. 2009 Sep;24(5):265-9. doi: 10.1097/YIC.0b013e32832e9b91.

PMID:
19629012
[PubMed - indexed for MEDLINE]
6.

The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study.

Selvi Y, Atli A, Aydin A, Besiroglu L, Ozdemir P, Ozdemir O.

Hum Psychopharmacol. 2011 Jan;26(1):51-7.

PMID:
21308781
[PubMed - indexed for MEDLINE]
7.

Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder.

Simon JS, Nemeroff CB.

J Clin Psychiatry. 2005 Oct;66(10):1216-20.

PMID:
16259533
[PubMed - indexed for MEDLINE]
8.

Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial).

Sayyah M, Sayyah M, Boostani H, Ghaffari SM, Hoseini A.

Depress Anxiety. 2012 Oct;29(10):850-4. doi: 10.1002/da.21996. Epub 2012 Aug 29.

PMID:
22933237
[PubMed - indexed for MEDLINE]
9.

Efficacy and safety of fluvoxamine in body dysmorphic disorder.

Phillips KA, Dwight MM, McElroy SL.

J Clin Psychiatry. 1998 Apr;59(4):165-71.

PMID:
9590666
[PubMed - indexed for MEDLINE]
10.

An open trial of aripiprazole augmentation for SSRI non-remitters with late-life depression.

Rutherford B, Sneed J, Miyazaki M, Eisenstadt R, Devanand D, Sackeim H, Roose S.

Int J Geriatr Psychiatry. 2007 Oct;22(10):986-91.

PMID:
17340654
[PubMed - indexed for MEDLINE]
11.

Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors.

Adson DE, Kushner MG, Fahnhorst TA.

J Affect Disord. 2005 May;86(1):99-104.

PMID:
15820277
[PubMed - indexed for MEDLINE]
12.

Aripiprazole augmentation in 39 adolescents with medication-resistant obsessive-compulsive disorder.

Masi G, Pfanner C, Millepiedi S, Berloffa S.

J Clin Psychopharmacol. 2010 Dec;30(6):688-93.

PMID:
21105283
[PubMed - indexed for MEDLINE]
13.

Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.

Lin CH, Lin SH, Jang FL.

J Clin Psychopharmacol. 2011 Oct;31(5):563-8. doi: 10.1097/JCP.0b013e31822bb0db.

PMID:
21869699
[PubMed - indexed for MEDLINE]
14.

Aripiprazole augmentation for a patient with partial remission of panic disorder.

Harada T, Yamada K, Sakamoto K, Ishigooka J.

J Clin Psychopharmacol. 2009 Jun;29(3):301-2. doi: 10.1097/JCP.0b013e3181a33456. No abstract available.

PMID:
19440089
[PubMed - indexed for MEDLINE]
15.

Chronic catatonia with obsessive compulsive disorder symptoms treated with lorazepam, memantine, aripiprazole, fluvoxamine and neurosurgery.

Mukai Y, Two A, Jean-Baptiste M.

BMJ Case Rep. 2011 Aug 4;2011. pii: bcr0220113858. doi: 10.1136/bcr.02.2011.3858.

PMID:
22687661
[PubMed - indexed for MEDLINE]
16.

Aripiprazole augmentation of clomipramine-refractory obsessive-compulsive disorder.

Friedman S, Abdallah TA, Oumaya M, Rouillon F, Guelfi JD.

J Clin Psychiatry. 2007 Jun;68(6):972-3. No abstract available.

PMID:
17592930
[PubMed - indexed for MEDLINE]
17.

A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study).

Fava M, Mischoulon D, Iosifescu D, Witte J, Pencina M, Flynn M, Harper L, Levy M, Rickels K, Pollack M.

Psychother Psychosom. 2012;81(2):87-97. doi: 10.1159/000332050. Epub 2012 Jan 25. Erratum in: Psychother Psychosom. 2012;81(4):261.

PMID:
22286203
[PubMed - indexed for MEDLINE]
18.

Placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder.

Phillips KA.

Am J Psychiatry. 2005 Feb;162(2):377-9.

PMID:
15677604
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remission.

Sheffrin M, Driscoll HC, Lenze EJ, Mulsant BH, Pollock BG, Miller MD, Butters MA, Dew MA, Reynolds CF 3rd.

J Clin Psychiatry. 2009 Feb;70(2):208-13. Epub 2009 Feb 10.

PMID:
19210951
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Delusionality and response to open-label fluvoxamine in body dysmorphic disorder.

Phillips KA, McElroy SL, Dwight MM, Eisen JL, Rasmussen SA.

J Clin Psychiatry. 2001 Feb;62(2):87-91.

PMID:
11247107
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk